Budesonide in inflammatory bowel disease.
Due to its immunomodulatory and anti-inflammatory properties glucocorticosteroids have proved to be highly efficacious in patients with inflammatory bowel disease. However, because of the risk of side-effects, the dose and duration of therapy with systemically acting glucocorticosteroids have to be restricted. Recently the use of topically acting glucocorticosteroids has attracted great interest. Among the various topically acting glucocorticosteroids budesonide has emerged as the most promising. Budesonide is highly potent, is readily water-soluble and has low systemic bioavailability, thus reducing the risk of corticosteroid-related side-effects. When given as enema to patients with proctitis or proctosigmoiditis, the efficacy of budesonide is greater than that of placebo and equal to that of prednisolone or 5-aminosalicylic acid enemas. In an enteric-coated formulation budesonide is more effective than placebo in achieving and maintaining remission in patients with ileocecal Crohn's disease. Although corticosteroid-related side-effects are rare, some suppression of the hypothalamic-pituitary-adrenal axis may occur.
Lamers
C B
CB
Department of Gastroenterology-Hepatology, University Hospital Leiden, Netherlands.
Wagtmans
M J
MJ
van der Sluys Veer
A
A
van Hogezand
R A
RA
Griffioen
G
G
D000284:Administration, Oral; D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D019819:Budesonide; D003093:Colitis, Ulcerative / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy; D003692:Delayed-Action Preparations; D004733:Enema; D005938:Glucocorticoids; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D011282:Pregnenediones / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D003692:Delayed-Action Preparations; D005938:Glucocorticoids; D011282:Pregnenediones; D019819:Budesonide